Congratulations to Petina Musara and Dr. Wadzanai Sameneka!

UZ-UCSF would like to congratulate two of our research scientists for leading and publishing two articles in high-impact journals. Published in AIDS and Behavior, Petina Musara led the authorship of a paper on how presenting drug detection levels in blood changed self-reports of study product adherence in the MTN 003 (VOICE) study.  MTN 003-D was […]

Continue Reading 0

Sharon Maxwell Community Impact Award

In 2015 the community created an award recognizing the diverse and expanding contributions of ACTG CAB members outside the network community commitments. The Sharon Maxwell Community Impact Award honors her over 20 year’s contributions to HIV education and support both in research related groups and for her community and state. This year’s award was won […]

Continue Reading 0

UZ-UCSF Researchers Featured on AllAfrica.com

UZ-UCSF researchers Lynda Stranix-Chibanda, Nyaradzo Mgodi, and Portia Hunidzarira were recently featured in an article posted on AllAfrica.com by Wallace Mawire, where they discuss the first ever HIV vaccine clinical trial that will soon be implemented in Zimbabwe. Known as HVTN 107, this study will be testing a similar vaccine used in Thailand’s RV144 trial, […]

Continue Reading 0

University of Zimbabwe’s Pro Vice Chancellor (Academic)’ tour of the UZ-UCSF Clinical Research Sites

University of Zimbabwe Pro Vice Chancellor (Academic), Professor Chipo Dyanda toured 5 UZ-UCSF Clinical Research sites (CRSs) on 12/March/2015 to familiarise herself with the research activities and infrastructure established to support these activities. The 5 CRSs are Spilhaus, St Mary’s, Zengeza, Seke South and Seke North. UZ-UCSF Executive Director, Professor Z Mike Chirenje led the […]

Continue Reading 0

Primary MTN 003 (VOICE) Study Results Published

MTN 003 (VOICE) primary study results have now been published in the 5 February 2015 issue of the New England Journal of Medicine (NEJM). Initially presented in 2013 at the 20th Conference of Retroviruses and Opportunistic Infections (CROI), greater details of those findings are now presented through this peer-review journal publication. Primary study results of […]

Continue Reading 0

IMPAACT P1078 Begins in Seke North and St. Mary’s

November and December 2014 were exciting months for Seke North and St. Mary’s CRSs, as they began screening and enrollment into IMPAACT P1078. This study is looking to see if INH (Isonizaid, a medication used to treat or prevent tuberculosis) protects HIV-infected pregnant women and their infants from contracting tuberculosis, and if starting INH during […]

Continue Reading 0

NIH-sponsored study identifies superior drug regimen for preventing mother-to-child HIV transmission

For HIV-infected women in good immune health, taking a three-drug regimen during pregnancy prevents mother-to-child HIV transmission more effectively than taking one drug during pregnancy, another during labor and two more after giving birth, an international clinical trial has found.  The ongoing PROMISE (Promoting Maternal-Infant Survival Everywhere) study also has found that one triple-drug regimen […]

Continue Reading 0

HPTN 076: Injectable PrEP

Client-centered models of HIV prevention for women which employ Pre Exposure Prophylaxis (PrEP) examine both drug effectiveness but also drug delivery. It has become critical to understand whether available delivery options are likely to be utilized given individual risk, preference and lifestyle. Most frequently offered as a pill, vaginal film, vaginal ring or gel, injectable […]

Continue Reading 0